Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C3 (Metformin, Digoxin, Simvastatin) in Advanced Solid Tumors
NCT03889795Phase 1Active, not recruiting
- Start
- Jun 2019
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs), simvastatin and digoxin in pancreatic cancer (PC) and solid tumor. Primary endpoint: Maximum Tolerated Dose and/or Recommended Dose up to 1 year. Started Jun 2019; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)simvastatindigoxin
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT03889795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889795.